New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
07:35 EDTPETXAratana Therapeutics initiates pivotal study for AT-001
Aratana Therapeutics announced the initiation of the pivotal field effectiveness study for AT-001, the company's innovative drug for treating pain in dogs with osteoarthritis. The randomized, blinded, multicenter pivotal study will enroll approximately 300 client-owned dogs with osteoarthritis, and will be conducted under a study protocol for which Aratana received concurrence from the FDA's Center for Veterinary Medicine. The primary endpoint will be a reduction in osteoarthritis pain compared to placebo, as indicated by the Canine Brief Pain Inventory scale, a well validated and widely used scoring system.
News For PETX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
07:18 EDTPETXAratana Therapeutics price target raised to $23 from $19 at Stifel
Subscribe for More Information
February 24, 2015
16:19 EDTPETXAratana Therapeutics to pay Elanco up to $3M to regains rights to AT-004
Subscribe for More Information
12:22 EDTPETXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:32 EDTPETXAratana Therapeutics initiated with a Buy at BofA/Merrill
Target $25.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use